Rapid Micro Biosystems, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Rapid Micro Biosystems reports increased revenue and positive gross margins for 2025, driven by system placements and strategic partnerships, despite continued net losses.
NASDAQ
Rapid Micro Biosystems' 2024 10-K filing highlights a year of financial losses but also strategic advancements, including a new distribution agreement and progress towards profitability.
NASDAQ
10-K: Rapid Micro Biosystems Details Capital Stock Structure and Regulatory Compliance in 10-K Filing
Rapid Micro Biosystems' 10-K filing outlines the company's capital stock structure, registration rights, anti-takeover measures, and compliance with SEC regulations.